Cell Therapy Automation: Technologies, Therapeutics, Strategies & Forecasts

“ Cell Therapy Automation: Technologies, Therapeutics, Strategies & Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing oncolytic segment of the immunological therapy sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, device designers, and industry strategists with a detailed understanding of the expanding impact of cell therapy on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving Cell Therapy Developments

Cell therapy has emerged as a promising new approach to treat malignancies that could only be treated on a palliative basis. Among those therapies, chimeric antigen receptor (CAR) modified T cell therapies has proved to be effective for hematological malignancies. To generate CAR T cells, patient- (autologous) or donor-derived (allogeneic) T cells are modified to express a CAR. The CAR is a chimeric construct containing at least one signaling domain of the T cell receptor and a single chain variable fragment (scFv).

The production of autologous CAR T cells is carried out by a variety of manufacturing approaches all comprising the same common steps. First, the patient's white blood cells (WBCs) are isolated by leukapheresis and washed. Then, the T cells are activated, transduced with the CAR transgene, expanded to the required cell numbers for therapy, formulated and filled. After quality control testing and preparatory lymphodepleting chemotherapy for the patient, the product is injected into the patient.

What You Will Learn:

• What current treatments are supplied as cell therapy treatments, how are they administered, what are the specifics, and who markets them?

• What cell Therapy treatments are in development, who are the developers, and what indications are they targeting?

• What are the major factors driving cell therapy demand?

• What is the size of the market today, who are the market share leaders, and what will the market share be in 2028?

• How important are drug developer relationships and what are the key alliances in the industry?

• What are the essential tech factors, technologies and market development issues for cell therapy products?

• What are the significant economic, technology, and regulatory factors affecting the market for cell therapy treatments?